Raltegravir

Raltegravir Uses, Dosage, Side Effects, Food Interaction and all others data.

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Raltegravir
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Raltegravir
Availability	Prescription only
Generic	Raltegravir
Raltegravir Other Names	Raltegravir
Related Drugs	Biktarvy, Truvada, tenofovir, ritonavir, zidovudine, abacavir, emtricitabine, Complera, Atripla, Stribild
Weight	100mg, 400mg, 600mg, 100mg, 25mg
Type	Oral granule for reconstitution, oral tablet, oral tablet, chewable
Formula	C₂₀H₂₁FN₆O₅
Weight	Average: 444.4163 Monoisotopic: 444.155746017
Protein binding	83%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Raltegravir is an antiretroviral agent used for the treatment of HIV infections in conjunction with other antiretrovirals.

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Raltegravir is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Post-exposure prophylaxis for occupational exposure to HIV therapy

How Raltegravir works

Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome. Raltegravir is primarily metabolized by glucuronidation.

Food Interaction

Take with or without food.

Raltegravir Drug Interaction

Minor: etravirine, ritonavirUnknown: contained in alcoholic beverages , aspirin, lorazepam, diphenhydramine, bictegravir / emtricitabine / tenofovir alafenamide, emtricitabine / tenofovir alafenamide, omega-3 polyunsaturated fatty acids, heparin, lithium, pregabalin, acetaminophen, darunavir, cholestyramine, vitamin a topical, bioflavonoids, emtricitabine / tenofovir, cholecalciferol, bupropion

Raltegravir Disease Interaction

Moderate: hemodialysis, liver disease, myopathy/rhabdomyolysis, PKU

Volume of Distribution

Approximately 83% bound to human plasma protein and is minimally distributed into red blood cells (blood-to-plasma partitioning ratio of 0.6).

Elimination Route

Absorbed from the gastrointestinal tract.

Half Life

9 hours

Clearance

The major mechanism of clearance of raltegravir in humans is glucuronidation mediated by UGT1A1, the renal clearance of unchanged drug is a minor pathway of elimination of raltegravir (9% of total dose).